Introduction: The objective was to evaluate the effect of hydrochlorothiazide and alendronate on urine calcium and bone mineral density in calcium stone-forming patients. Material and Methods: A prospective, non-randomized, non-observational comparative study was performed; this study included 111 patients with recurrent calcium stones, divided into 3 groups according to the treatment received. Group 1: 36 patients were treated with alendronate, 70 mg/week; Group 2: 34 patients were treated with alendronate, 70 mg/week + hydrochlorothiazide, 50 mg/day; Group 3: 41 patients were treated with hydrochlorothiazide, 50 mg/day. All patients received recommendations on diet and fluid intake. Other variables of bone mineral density were studied and analyzed, including bone remodeling markers and urinary calcium before and after 2 years of treatment. The statistical analysis was performed using the SPSS 17.0 program, with a statistical significance of p < 0.05. Results: After 2 years of treatment, a significant difference was observed in the β-crosslaps and a bone mineral density improvement in Group 1, along with a decrease in urinary calcium. In Group 3, a statistically significant difference was found in urinary calcium and fasting calcium/creatinine ratio, as well as an improvement in bone mineral density after 2 years of medical treatment. In Group 2 patients treated with the combination, there was an improvement in bone mineral density and a decrease in the β-crosslaps marker similar to patients in Group 1, and a decrease in urinary calcium similar to those in Group 3. Conclusion: Combined alendronate + hydrochlorothiazide treatment offers the best results along with the improvement in bone mineral density and decrease in urine calcium in patients with recurrent calcium stones.

Keywords:
Alendronate, Calciuria, Thiazides, Bone mineral density
1.
Grases F, Costa-Bauza A, Prieto RM: Renal lithiasis and nutrition. Nutr J 2006;5:23.
2.
Sfoungaristos S, Gofrit ON, Yutkin V, Pode D, Duvdevani M: Prevention of renal stone disease recurrence. A systematic review of contemporary pharmaceutical options. Expert Opin Pharmacother 2015;16:1209-1218.
3.
Eisner BH, Goldfarb DS, Pareek G: Pharmacologic treatment of kidney stone disease. Urol Clin North Am 2013;40:21-30.
4.
Wolfgram DF, Gundu V, Astor BC, Jhagroo RA: Hydrochlorothiazide compared to chlorthalidone in reduction of urinary calcium in patients with kidney stones. Urolithiasis 2013;41:315-322.
5.
Arrabal-Martín M, Fernández-Rodríguez A, Arrabal-Polo MA, García-Ruiz MJ, Zuluaga-Gómez A: Extracorporeal renal lithotripsy: evolution of residual lithiasis treated with thiazides. Urology 2006;68:956-959.
6.
Laroche M, Mazières B: Beneficial effect of a thiazide diuretic on bone mineral density in male osteoporosis with hypercalciuria. Clin Exp Rheumatol 1998;16:109-110.
7.
Suárez Fernández C, Ruilope Urioste LM: [Thiazide diuretics and calcium metabolism: role in renal lithiasis and osteoporosis]. An Med Interna 1996;13:401-406.
8.
Yasui T, Niimi K, Hirose M: [New therapy using bisphosphonate for urolithiasis]. Clin Calcium 2011;21:1511-1515.
9.
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS: Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999;55:234-243.
10.
Senzaki H, Yasui T, Okada A, Ito Y, Tozawa K, Kohri K: Alendronate inhibits urinary calcium microlith formation in a three-dimensional culture model. Urol Res 2004;32:223-228.
11.
Arrabal-Polo MA, Arias-Santiago S, de Haro-Muñoz T, Lopez-Ruiz A, Orgaz-Molina J, Gonzalez-Torres S, Zuluaga-Gomez A, Arrabal-Martin M: Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis, hypercalciuria, and recurring renal calcium lithiasis. Urology 2013;81:731-737.
12.
Vigen R, Weideman RA, Reilly RF: Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol 2011;43:813-819.
13.
Ceylan K, Topal C, Erkoc R, Sayarlioglu H, Can S, Yilmaz Y, et al: Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease. Ann Pharmacother 2005;39:1034-1038.
14.
LaCroix AZ, Ott SM, Ichikawa L, Scholes D, Barlow WE: Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000;133:516-526.
15.
Reid IR, Ames RW, Orr-Walker BJ, Clearwater JM, Horne AM, Evans MC, et al: Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000;109:362-370.
16.
Sigurdsson G, Franzson L: Increased bone mineral density in a population-based group of 70-year-old women on thiazide diuretics, independent of parathyroid hormone levels. J Intern Med 2001;250:51-56.
17.
Legroux-Gerot I, Catanzariti L, Marchandise X, Duquesnoy B, Cortet B: Bone mineral density changes in hypercalciuretic osteoporotic men treated with thiazide diuretics. Joint Bone Spine 2004;71:51-55.
18.
Kruse C, Eiken P, Vestergaard P: Continuous and long-term treatment is more important than dosage for the protective effect of thiazide use on bone metabolism and fracture risk. J Intern Med 2016;279:110-112.
19.
Huen SC, Goldfarb DS: Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol 2007;177:1238-1243.
20.
Arrabal-Polo MA, Arrabal-Martin M, de Haro-Munoz T, Lopez-Leon VM, Merino-Salas S, Ochoa-Hortal MA, et al: Mineral density and bone remodelling markers in patients with calcium lithiasis. BJU Int 2011;108:1903-1908.
21.
Bijelic R, Milicevic S, Balaban J: Incidence of osteoporosis in patients with urolithiasis. Med Arch 2014;68:335-338.
22.
Caudarella R, Vescini F, Buffa A, La Manna G, Stefoni S: Osteoporosis and urolithiasis. Urol Int 2004;72(suppl 1):17-19.
23.
Gosch M, Kammerlander C, Nicholas JA: Treatment of osteoporosis in older adults. Panminerva Med 2014;56:133-143.
24.
Yasui T, Itoh Y, Okada A, Hamamoto S, Hirose M, Kobayashi T, et al: Alendronate reduces the excretion of risk factors for calcium phosphate stone formation in postmenopausal women with osteoporosis. Urol Int 2009;83:226-229.
25.
Watanabe Y, Ohshima H, Mizuno K, Sekiguchi C, Fukunaga M, Kohri K, Rittweger J, Felsenberg D, Matsumoto T, Nakamura T: Intravenous pamidronate prevents femoral bone loss and renal stone formation during 90-day bed rest. J Bone Miner Res 2004;19:1771-1778.
26.
Ruml LA, Dubois SK, Roberts ML, Pak CY: Prevention of hypercalciuria and stone-forming propensity during prolonged bedrest by alendronate. J Bone Miner Res 1995;10:655-662.
27.
Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, et al: Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. Nephrol Dial Transplant 2009;24:1472-1477.
28.
Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW: Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int 2011;79:393-403.
29.
Lotan Y, Pearle MS: Economics of stone management. Urol Clin North Am 2007;34:443-453.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.